Table 3 Adverse reactions
Fosaprepitant group | Control group | p-value | |
N = 112 courses | N = 116 courses | ||
n (%) | n (%) | ||
Laboratory markers | |||
Increase ALT (n.v. ≤ 39 U/L) | |||
≥ 1.5 x normal value | 7 (6.3) | 6 (5.2) | 0.9481 |
≥ 2.5 x normal value | 7 (6.3) | 8 (6.9) | 0.8439 |
Increase AST (n.v. ≤ 59 U/L) | |||
≥ 1.5 x normal value | 7 (6.3) | 5 (4.3) | 0.7195 |
≥ 2.5 x normal value | 1 (0.9) | 3 (2.6) | 0.6390 |
Increase total bilirubin (n.v. ≤ 1.1 mg/dL) | |||
≥ 1.5 x normal value | 1 (0.9) | 2 (1.7) | > 0.9999 |
≥ 2.5 x normal value | 0 (0.0) | 1 (0.9) | > 0.9999 |
Increase creatinine (n.v. ≤ 0.7 mg/dL) | |||
≥ 1.5 x normal value | 0 (0.0) | 3 (2.6) | 0.2577 |
≥ 2.5 x normal value | 0 (0.0) | 0 (0.0) | – |
Increase urea (n.v. ≤ 46 mg/dL) | |||
≥ 1.5 x normal value | 1 (0.9) | 0 (0.0) | 0.986 |
≥ 2.5 x normal value | 0 (0.0) | 1 (0.9) | > 0.9999 |
Decrease potassium (n.v. ≥ 3.4 mmol/L - 4.9 mmol/L) | |||
< 3.4 mmol/L | 4 (3.6) | 6 (5.2) | 0.7897 |
< 2.4 mmol/L | 0 (0.0) | 0 (0.0) | – |
Decrease calcium (n.v. ≥ 2.0 mmol/L - 2.6 mmol/L) | |||
< 2.0 mmol/L | 12 (10.7) | 7 (6.0) | 0.2397 |
< 1.8 mmol/L | 0 (0.0) | 0 (0.0) | – |
Decrease sodium (n.v. 134–145 mmol/L) | |||
< 134 mmol/L | 14 (12.5) | 23 (19.8) | 0.1867 |
< 130 mmol/L | 2 (1.8) | 1 (0.9) | 0.9756 |
Adverse reactions | |||
Exanthema | 1 (0.9) | 0 (0.0) | 0.3302 |
Sweating | 3 (2.7) | 2 (1.7) | 0.6228 |
Fever | 5 (4.5) | 10 (8.6) | 0.2864 |
Loss of appetite | 3 (2.7) | 2 (1.7) | 0.2057 |
Diarrhea | 15 (13.4) | 14 (12.1) | 0.6228 |
Obstipation | 4 (3.6) | 3 (2.6) | 0.7642 |